These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

428 related items for PubMed ID: 14609619

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Phosphodiesterase type 5 inhibitors: molecular pharmacology and interactions with other phosphodiesterases.
    Seftel AD.
    Curr Pharm Des; 2005; 11(31):4047-58. PubMed ID: 16378510
    [Abstract] [Full Text] [Related]

  • 3. In vitro effects of PDE5 inhibitors sildenafil, vardenafil and tadalafil on isolated human ureteral smooth muscle: a basic research approach.
    Gratzke C, Uckert S, Kedia G, Reich O, Schlenker B, Seitz M, Becker AJ, Stief CG.
    Urol Res; 2007 Feb; 35(1):49-54. PubMed ID: 17102958
    [Abstract] [Full Text] [Related]

  • 4. The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil.
    Saenz de Tejada I, Angulo J, Cuevas P, Fernández A, Moncada I, Allona A, Lledó E, Körschen HG, Niewöhner U, Haning H, Pages E, Bischoff E.
    Int J Impot Res; 2001 Oct; 13(5):282-90. PubMed ID: 11890515
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Nebivolol potentiates the efficacy of PDE5 inhibitors to relax corpus cavernosum and penile arteries from diabetic patients by enhancing the NO/cGMP pathway.
    Martínez-Salamanca JI, La Fuente JM, Cardoso J, Fernández A, Cuevas P, Wright HM, Angulo J.
    J Sex Med; 2014 May; 11(5):1182-92. PubMed ID: 24877179
    [Abstract] [Full Text] [Related]

  • 7. New phosphodiesterase type 5 inhibitors in the management of erectile dysfunction.
    Mason RG.
    J R Soc Promot Health; 2003 Jun; 123(2):79-80. PubMed ID: 12852189
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Pharmacologic update: treatment of erectile dysfunction in the elderly with phosphodiesterase type 5 inhibitors: cardiovascular implications.
    Agarwal P, Sander GE, Giles TD.
    Am J Geriatr Cardiol; 2004 Jun; 13(6):332-5. PubMed ID: 15538074
    [No Abstract] [Full Text] [Related]

  • 10. Inhibitors of phosphodiesterase 5 (PDE 5) inhibit the nerve-induced release of nitric oxide from the rabbit corpus cavernosum.
    Hallén K, Wiklund NP, Gustafsson LE.
    Br J Pharmacol; 2007 Feb; 150(3):353-60. PubMed ID: 17179943
    [Abstract] [Full Text] [Related]

  • 11. Phosphodiesterase-5 inhibitors and their hemodynamic effects.
    Prisant LM.
    Curr Hypertens Rep; 2006 Aug; 8(4):345-51. PubMed ID: 16884667
    [Abstract] [Full Text] [Related]

  • 12. Phosphodiesterase type 5 as a pharmacologic target in erectile dysfunction.
    Corbin JD, Francis SH, Webb DJ.
    Urology; 2002 Sep; 60(2 Suppl 2):4-11. PubMed ID: 12414329
    [Abstract] [Full Text] [Related]

  • 13. Differential effects of phosphodiesterase-5 inhibitors on hypoxic pulmonary vasoconstriction and pulmonary artery cytokine expression.
    Tsai BM, Turrentine MW, Sheridan BC, Wang M, Fiore AC, Brown JW, Meldrum DR.
    Ann Thorac Surg; 2006 Jan; 81(1):272-8. PubMed ID: 16368379
    [Abstract] [Full Text] [Related]

  • 14. The role of PDE5 inhibitors in heme oxygenase-cGMP relationship in rat cavernous tissues.
    Aziz MT, Mostafa T, Atta H, Rashed L, Marzouk SA, Obaia EM, Sabry D, Hassouna AA, El-Shehaby AM, Aziz AT.
    J Sex Med; 2008 Jul; 5(7):1636-45. PubMed ID: 18208506
    [Abstract] [Full Text] [Related]

  • 15. Phosphodiesterase-5 inhibitors: clinical market and basic science comparative studies.
    McCullough A.
    Curr Urol Rep; 2004 Dec; 5(6):451-9. PubMed ID: 15541215
    [Abstract] [Full Text] [Related]

  • 16. Binding of tritiated sildenafil, tadalafil, or vardenafil to the phosphodiesterase-5 catalytic site displays potency, specificity, heterogeneity, and cGMP stimulation.
    Blount MA, Beasley A, Zoraghi R, Sekhar KR, Bessay EP, Francis SH, Corbin JD.
    Mol Pharmacol; 2004 Jul; 66(1):144-52. PubMed ID: 15213306
    [Abstract] [Full Text] [Related]

  • 17. Mechanisms of action of PDE5 inhibition in erectile dysfunction.
    Corbin JD.
    Int J Impot Res; 2004 Jun; 16 Suppl 1():S4-7. PubMed ID: 15224127
    [Abstract] [Full Text] [Related]

  • 18. Differential effects of the phosphodiesterase type 5 inhibitors sildenafil, vardenafil, and tadalafil in rat aorta.
    Teixeira CE, Priviero FB, Webb RC.
    J Pharmacol Exp Ther; 2006 Feb; 316(2):654-61. PubMed ID: 16204472
    [Abstract] [Full Text] [Related]

  • 19. Efficacy of tadalafil in men with erectile dysfunction naïve to phosphodiesterase 5 inhibitor therapy compared with prior responders to sildenafil citrate.
    Broderick GA, Donatucci CF, Hatzichristou D, Torres LO, Valiquette L, Zhao Y, Loughney K, Sides GD, Ahuja S.
    J Sex Med; 2006 Jul; 3(4):668-675. PubMed ID: 16839323
    [Abstract] [Full Text] [Related]

  • 20. Mechanisms of direct relaxant effect of sildenafil, tadalafil and vardenafil on corpus cavernosum.
    Lau LC, Adaikan PG.
    Eur J Pharmacol; 2006 Jul 17; 541(3):184-90. PubMed ID: 16777087
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.